Q32 Bio reels in $60m Series B
Cambridge, Massachusetts-based Q32 Bio, a developer of biologic therapeutics to restore healthy immune regulation, has closed $60 million in Series B financing.
Cambridge, Massachusetts-based Q32 Bio, a developer of biologic therapeutics to restore healthy immune regulation, has closed $60 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination